US20220235348A1
University of Texas System
Methods for reversing one or more mutations in the telomerase (TERT) promoter are provided and may be used to treat a cancer. In some embodiments, programmable base editing (PBE) is used to correct a mutated TERT promoter (e.g., −124 C>T, −228C>T, or −250C>T to −124 C, −228C, or −250C, …